The antibody-mediated rejection prevention market in the United States and United Kingdom is a rapidly growing segment of the healthcare industry. Antibody-mediated rejection (AMR) is a severe form of rejection that can occur after organ transplantation and requires prompt treatment. As a result, there is an increased demand for AMR prevention solutions and treatments in these countries, driving growth in the market. Companies and research organizations are investing heavily in the development of new drugs, therapies and diagnostics to improve the prognosis of organ transplant patients and reduce the risk of AMR

NEWARK, Del, Feb. 06, 2023 (GLOBE NEWSWIRE) -- The global antibody-mediated rejection prevention market is predicted to reach a valuation of US$ 89 million in 2023, with a compound annual growth rate (CAGR) of 16%, as per a recently published FMI report. Over the last decade, the complement system has emerged as an important constituent of the AMR market.

Technological innovations, such as genomic research and donor-specific antibody identification and definition assays, have provided crucial information into the pathophysiology and treatment of severe antibody-mediated rejection. As a result, this aspect largely contributed to the antibody-mediated rejection prevention industry. Furthermore, Asia Pacific is expected to experience the fastest CAGR owing to the rising number of clinical trial research pertaining to several drugs and the region's expanding geriatric population.

Get the Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16632

The citizenry with end-stage renal impairment is getting older. As in almost half of all new patient populations exceed the age of 65, and one-third are over the age of 70. As a consequence, late kidney transplant failure is pervasive in older people, which is anticipated to propel the antibody-mediated rejection prevention market over the coming years. According to a Pew Research Center report, the aged population in the United States will augment to 81 million by 2050, up from 37 million in 2005. As a result, this factor is expected to contribute to market expansion.

Key Takeaways from the Market Study

• The immunomodulators market is expected to grow at a CAGR of 6.3% over the forecast period.

• From 2018 to 2022, sales increased significantly at a CAGR of 14%.

• The global monoclonal antibodies segment was worth US$ 186 million in 2021

• The global monoclonal antibodies segment is expected to grow at a CAGR of 11% between 2023 and 2033.

• The global market for antibody-mediated rejection prevention is expected to be worth US$ 528.31 million.
  

“The population of people with end-stage kidney disease is getting older. Nearly half of all new patient populations are over 65, with one-third being over 70. As a result, late kidney transplant failure is common among the elderly, which is expected to drive the antibody-mediated rejection prevention market,” says the FMI analyst.

Talk with Research Expert: https://www.futuremarketinsights.com/ask-question/rep-gb-16632

Key Market Players

• CSL Behring

• Hansa Biopharma

• Sanofi

• Talaris Therapeutics

• Horizon Therapeutics

• Novartis AG

• Biogen

• Teva Pharmaceutical Industries Ltd.

• Eli Lilly and Company

• Bristol-Myers & Squibb Company

Some of the latest developments are below:

• Horizon Therapeutics plc disclosed in February 2021 that it will purchase Viela Bio, Inc. to substantially expand its product portfolio and flourish its rare disease medical portfolio.

• The trial's Independent Data Monitoring Committee has recommended that the evaluation of Jardiance® (empagliflozin) in grownups with chronic kidney disease (CKD) be halted early. Following an official interim analysis that fulfilled predefined criteria for favorable efficacy, the Medical Research Council (MRC) Population Health Research Unit reported in March 2022.

Buy Complete Report: https://www.futuremarketinsights.com/checkout/16632

Key Segments Profiled in the Antibody-mediated Rejection Prevention Market Survey

By Treatment:

• Monoclonal Antibodies

• Cysteine Protease Inhibitors

• Immunomodulators

• Plasmapheresis

By End User:

• Hospitals

• Specialty Clinics

Table of Content

1. Executive Summary

  1.1. Global Market Outlook
    1.2. Demand-side Trends
    1.3. Supply-side Trends
    1.4. Technology Roadmap Analysis
    1.5. Analysis and Recommendations

2. Market Overview

  2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations

Browse Full Report: https://www.futuremarketinsights.com/reports/antibody-mediated-rejection-prevention-market

Have a Look at Related Research Reports of Healthcare Domain:

Durable Medical Equipment Rental Market Growth - A newly released Durable Medical Equipment Rental Market analysis report by Future Market Insights reveals that revenue through the Durable Medical Equipment Rental Market in 2022 was held at US$ 25.7 billion. With a CAGR of 5.7% from 2023 to 2033, the market is projected to reach a valuation of US$ 47 billion by 2033.

Pork Tapeworm Infection Treatment Market Size - The global pork tapeworm infection treatment market is expected to reach US$ 11.66 Billion in 2023 and is projected to exhibit a CAGR of 8% from 2023 to 2033.

Marburg Virus Disease Therapeutics Market Share - The global Marburg virus disease therapeutics market is expected to garner a market value of US$ 90.74 Million in 2023 and is expected to accumulate a market value of US$ 155 Million by registering a CAGR of 5.5% in the forecast period 2023 to 2033.

Cold Disposable Biopsy Forceps Market Forecast - The global cold disposable biopsy forceps market is expected to enjoy a valuation of US$ 634.6 Million by 2023, and further expand at a CAGR of 8.2% to reach a valuation of ~US$ 1.40 Billion by the year 2033.

Instrument Cleaners & Detergents Market Trends - The global market holds a valuation of US$ 2.1 billion in the year 2022, and is expected to further expand at a CAGR of 4.0% to reach a valuation of US$ 3.2 billion by the year 2033.

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S., and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
LinkedIn| Twitter| Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com